Is Annovis Bio Stock a Good Investment?
Annovis Bio Investment Advice | ANVS |
- Examine Annovis Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Annovis Bio's leadership team and their track record. Good management can help Annovis Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Annovis Bio's business and its evolving consumer preferences.
- Compare Annovis Bio's performance and market position to its competitors. Analyze how Annovis Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Annovis Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Annovis Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Annovis Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Annovis Bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Annovis Bio Stock
Researching Annovis Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.22. Annovis Bio had not issued any dividends in recent years.
To determine if Annovis Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Annovis Bio's research are outlined below:
| Annovis Bio generated a negative expected return over the last 90 days | |
| Annovis Bio has high historical volatility and very poor performance | |
| Annovis Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (56.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Annovis Bio currently holds about 35.97 M in cash with (39.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41. | |
| Annovis Bio has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20 Key Pharma Companies Actively Working in the Therapeutics Segment DelveInsight DelveInsight |
Annovis Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Annovis Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Annovis Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Annovis Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Annovis Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-10 | 2024-03-31 | -0.8 | -0.72 | 0.08 | 10 | ||
2021-11-03 | 2021-09-30 | -0.44 | -0.35 | 0.09 | 20 | ||
2021-03-03 | 2020-12-31 | -0.16 | -0.25 | -0.09 | 56 | ||
2022-05-04 | 2022-03-31 | -0.58 | -0.72 | -0.14 | 24 | ||
2020-07-29 | 2020-06-30 | -0.15 | -0.34 | -0.19 | 126 | ||
2024-08-14 | 2024-06-30 | -0.63 | -0.32 | 0.31 | 49 | ||
2022-08-08 | 2022-06-30 | -0.64 | -1.07 | -0.43 | 67 | ||
2024-11-06 | 2024-09-30 | -0.53 | -0.97 | -0.44 | 83 |
Know Annovis Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Annovis Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Annovis Bio backward and forwards among themselves. Annovis Bio's institutional investor refers to the entity that pools money to purchase Annovis Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 24.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 22.1 K | Northern Trust Corp | 2024-09-30 | 21.9 K | Spears Abacus Advisors Llc | 2024-09-30 | 20 K | Bank Of New York Mellon Corp | 2024-09-30 | 19.1 K | Greenwich Wealth Management Llc | 2024-09-30 | 16.5 K | Bank Of Montreal | 2024-09-30 | 13.5 K | Bmo Capital Markets Corp. | 2024-09-30 | 13.5 K | Lokken Investment Group Llc | 2024-09-30 | 12.2 K | Vanguard Group Inc | 2024-09-30 | 380.3 K | Citadel Advisors Llc | 2024-09-30 | 102.7 K |
Annovis Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 92.58 M.Market Cap |
|
Annovis Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.51) | (5.23) | |
| Return On Capital Employed | (7.60) | (7.22) | |
| Return On Assets | (5.51) | (5.23) | |
| Return On Equity | 7.25 | 7.61 |
Determining Annovis Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Annovis Bio is a good buy. For example, gross profit margin measures Annovis Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Annovis Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Annovis Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annovis Bio. Check Annovis Bio's Beneish M Score to see the likelihood of Annovis Bio's management manipulating its earnings.
Evaluate Annovis Bio's management efficiency
Annovis Bio has return on total asset (ROA) of (1.5458) % which means that it has lost $1.5458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.967) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 7.61 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23). At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.86) | (0.82) | |
| Tangible Book Value Per Share | (0.86) | (0.82) | |
| Enterprise Value Over EBITDA | (4.16) | (3.95) | |
| Price Book Value Ratio | (21.77) | (20.68) | |
| Enterprise Value Multiple | (4.16) | (3.95) | |
| Price Fair Value | (21.77) | (20.68) | |
| Enterprise Value | 73.1 M | 44.9 M |
The leadership approach at Annovis Bio's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.704 |
Basic technical analysis of Annovis Stock
As of the 2nd of December, Annovis Bio shows the Mean Deviation of 3.21, standard deviation of 4.23, and Risk Adjusted Performance of (0.05). Annovis Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Annovis Bio standard deviation and potential upside to decide if Annovis Bio is priced correctly, providing market reflects its regular price of 7.28 per share. Given that Annovis Bio has information ratio of (0.11), we suggest you to validate Annovis Bio's prevailing market performance to make sure the company can sustain itself at a future point.Annovis Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Annovis Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Hoffman few days ago Disposition of 222222 shares by Michael Hoffman of Annovis Bio subject to Rule 16b-3 | ||
Maria Maccecchini over a month ago Acquisition by Maria Maccecchini of 21312 shares of Annovis Bio subject to Rule 16b-3 | ||
Maria Maccecchini over six months ago Disposition of 3000 shares by Maria Maccecchini of Annovis BioInc subject to Rule 16b-3 | ||
Reid McCarthy over six months ago Disposition of tradable shares by Reid McCarthy of Annovis BioInc subject to Rule 16b-3 | ||
Michael Hoffman over a year ago Acquisition by Michael Hoffman of 163880 shares of Annovis BioInc subject to Rule 16b-3 | ||
Michael Hoffman over a year ago Acquisition by Michael Hoffman of 164745 shares of Annovis BioInc subject to Rule 16b-3 | ||
Maria Maccecchini over a year ago Bona fide gift to Maria Maccecchini of 3000 shares of Annovis BioInc subject to Section 16 |
Annovis Bio's Outstanding Corporate Bonds
Annovis Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Annovis Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Annovis bonds can be classified according to their maturity, which is the date when Annovis Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Annovis Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Annovis Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 3.21 | |||
| Coefficient Of Variation | (1,330) | |||
| Standard Deviation | 4.23 | |||
| Variance | 17.93 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 21.75 | |||
| Value At Risk | (5.94) | |||
| Potential Upside | 6.62 | |||
| Skewness | 0.9754 | |||
| Kurtosis | 1.34 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 3.21 | |||
| Coefficient Of Variation | (1,330) | |||
| Standard Deviation | 4.23 | |||
| Variance | 17.93 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 21.75 | |||
| Value At Risk | (5.94) | |||
| Potential Upside | 6.62 | |||
| Skewness | 0.9754 | |||
| Kurtosis | 1.34 |
Consider Annovis Bio's intraday indicators
Annovis Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Annovis Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 35407.68 | |||
| Daily Balance Of Power | 0.8906 | |||
| Rate Of Daily Change | 1.08 | |||
| Day Median Price | 7.07 | |||
| Day Typical Price | 7.14 | |||
| Price Action Indicator | 0.5 | |||
| Period Momentum Indicator | 0.57 |
Annovis Bio Corporate Filings
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 3rd of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of June 2024 Other Reports | ViewVerify |
Annovis Stock media impact
Far too much social signal, news, headlines, and media speculation about Annovis Bio that are available to investors today. That information is available publicly through Annovis media outlets and privately through word of mouth or via Annovis internal channels. However, regardless of the origin, that massive amount of Annovis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Annovis Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Annovis Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Annovis Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Annovis Bio alpha.
Annovis Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Annovis Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Annovis Bio Corporate Management
| Hilda Maibach | Senior Statistics | Profile | |
| Michael Hoffman | Independent Director Chairman of the Board | Profile | |
| RAC MS | Senior Operations | Profile | |
| Claudine Bruck | Independent Director | Profile | |
| MBA III | Chief Officer | Profile |
Already Invested in Annovis Bio?
The danger of trading Annovis Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Annovis Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Annovis Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Annovis Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.